tbuckley/cabot-search huggingface dataset:
Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study
Authors: Sergey E. Borisov, Keertan Dheda, Martin Enwerem, Rodolfo Romero Leyet, Lia D'Ambrosio, Rosella Centis, Giovanni Sotgiu, Simon Tiberi, Jan-Willem Alffenaar, Andrey Maryandyshev, Evgeny Belilovski, Shashank Ganatra, Alena Skrahina, Onno Akkerman, Alena Aleksa, Rohit Amale, Janina Artsukevich, Judith Bruchfeld, Jose A. Caminero, Isabel Carpena Martinez, Luigi Codecasa, Margareth Dalcolmo, Justin Denholm, Paul Douglas, Raquel Duarte, Aliasgar Esmail, Mohammed Fadul, Alexey Filippov, Lina Davies Forsman, Mina Gaga, Julia-Amaranta Garcia-Fuertes, José-María García-García, Gina Gualano, Jerker Jonsson, Heinke Kunst, Jillian S. Lau, Barbara Lazaro Mastrapa, Jorge Lazaro Teran Troya, Selene Manga, Katerina Manika, Pablo González Montaner, Jai Mullerpattan, Suzette Oelofse, Martina Ortelli, Domingo Juan Palmero, Fabrizio Palmieri, Antonella Papalia, Apostolos Papavasileiou, Marie-Christine Payen, Emanuele Pontali, Carlos Robalo Cordeiro, Laura Saderi, Tsetan Dorji Sadutshang, Tatsiana Sanukevich, Varvara Solodovnikova, Antonio Spanevello, Sonam Topgyal, Federica Toscanini, Adrian R. Tramontana, Zarir Farokh Udwadia, Pietro Viggiani, Veronica White, Alimuddin Zumla, Giovanni Battista Migliori
Journal: European Respiratory Journal (2017)

Large studies on bedaquiline used to treat multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB) are lacking. This study aimed to evaluate the safety and effectiveness of bedaquiline-containing regimens in a large, retrospective, observational study conducted in 25 centres and 15 countries in five continents.428 culture-confirmed MDR-TB cases were analysed (61.5% male; 22.1% HIV-positive, 45.6% XDR-TB). MDR-TB cases were admitted to hospital for a median (interquartile range (IQR)) 179 (92-280) days and exposed to bedaquiline for 168 (86-180) days. Treatment regimens included, among others, linezolid, moxifloxacin, clofazimine and carbapenems (82.0%, 58.4%, 52.6% and 15.3% of cases, respectively).Sputum smear and culture conversion rates in MDR-TB cases were 63.6% and 30.1%, respectively at 30 days, 81.1% and 56.7%, respectively at 60 days; 85.5% and 80.5%, respectively at 90 days and 88.7% and 91.2%, respectively at the end of treatment. The median (IQR) time to smear and culture conversion was 34 (30-60) days and 60 (33-90) days. Out of 247 culture-confirmed MDR-TB cases completing treatment, 71.3% achieved success (62.4% cured; 8.9% completed treatment), 13.4% died, 7.3% defaulted and 7.7% failed. Bedaquiline was interrupted due to adverse events in 5.8% of cases. A single case died, having electrocardiographic abnormalities that were probably non-bedaquiline related.Bedaquiline-containing regimens achieved high conversion and success rates under different nonexperimental conditions.
Current Challenges Associated With Next-Generation Sequencing of Breast Cancer—Reply
Authors: Polly Niravath, Burcu Cakar, Matthew Ellis
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Comparison of test results and clinical outcomes of patients assessed with both MammaPrint and Oncotype DX with pathologic variables: An independent study.
Authors: David J. Dabbs, Adam Brufsky, Rachel Catherine Jankowitz, Shannon Puhalla, Adrian Lee, Steffi Oesterreich, Barry C. Lembersky, Rohit Bhargava
Journal: Journal of Clinical Oncology (2014)

550 Background: There are no comparisons between test results of MammaPrint and Oncotype DX. Methods: Oncotype DX (ODX) recurrence score (RS) on 437 patients with pathologically characterized ER+ tumors who had a minimum of 5 years follow-up from diagnosis was compared with MammaPrint (MP), BluePrint (BP) and TargetPrint (TP). Results: Of 301 MP low risk cases, 191 were low risk by ODX (63% agreement) and of 136 MP high risk, 63 were high risk by ODX (46%). Of ODX intermediate risk cases (161), 104 of were MP low risk (65%), 57 (35%) were MP high risk. Of BP low risk luminal tumors, 188/287(66%) were ODX low, 95/287 (33%) ODX intermediate, and 4/287 (1%) ODX high risk (Table). Tumor grade was significantly correlated at P<.0001 with risk assessment by both tests. BP class was correlated with ER, PR and HER2 results. Overall agreement between clinical ER, PR, HER2 (IHC+FISH) results with TP results were 92% (401/435), 85% (370/436), 95% (412/435), but percent positive agreement for HER2 was only 50% (20 of 40 unequivocally HER2 positive cases identified correctly by TP). Four percent of ODX low risk, 34% of intermediate and 77% of ODX high risk ODX patients received chemotherapy. There were 7 distant recurrences: 4 were MP high, 3 MP low; For ODX, 5 were intermediate, 1 high,1 low (Table). Conclusions: (1) There are real differences in risk assignments between MP and ODX that may affect treatment decisions. (2) There was close correlation between pathologic variables and MP and BP, but HER2 TP -FISH/IHC agreement is low. (3) Further follow-up of this cohort is required, along with prospective trials, to determine clinical utility of these tests compared to pathologic analysis. MammaPrint versus Oncotype Dx. RS RS RS MammaPrint BluePrint High *1 Intermediate *5 Low *1 Total High risk MP Basal-like 8 2 10 ERBB2 *2 28 8 36 Luminal-like *2 27 47 16 90 High risk total 63 57 16 136 Low risk MP ERBB2 2 9 3 14 Luminal-like *3 4 95 188 287 Low risk total 6 104 191 301 Grand total 69 161 207 437 * Distant recurrences.
Current Challenges Associated With Next-Generation Sequencing of Breast Cancer
Authors: Steven Sorscher
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Curcumin-3,4-Dichloro Phenyl Pyrazole (CDPP) overcomes curcumin's low bioavailability, inhibits adipogenesis and ameliorates dyslipidemia by activating reverse cholesterol transport
Authors: Abhishek Gupta, Vinay Kumar Singh, Durgesh Kumar, Pragya Yadav, Santosh Kumar, Muheeb Beg, Kripa Shankar, Salil Varshney, Sujith Rajan, Ankita Srivastava, Rakhi Choudhary, Vishal M. Balaramnavar, Rabi Bhatta, Narender Tadigoppula, Anil Nilkanth Gaikwad
Journal: Metabolism (2017)
Circular RNA circMTO1 acts as the sponge of microRNA‐9 to suppress hepatocellular carcinoma progression
Authors: Dan Han, Jiangxue Li, Huamin Wang, Xiaoping Su, Jin Hou, Yan Gu, Cheng Qian, Yun Lin, Xiang Liu, Mingyan Huang, Nan Li, Weiping Zhou, Yizhi Yu, Xuetao Cao
Journal: Hepatology (2017)

Noncoding RNAs play important roles in cancer biology, providing potential targets for cancer intervention. As a new class of endogenous noncoding RNAs, circular RNAs (circRNAs) have been recently identified in cell development and function, and certain types of pathological responses, generally acting as a microRNA (miRNA) sponge to regulate gene expression. Identifying the deregulated circRNAs and their roles in cancer has attracted much attention. However, the expression profile and function of circRNAs in human hepatocellular carcinoma (HCC) remain to be investigated. Here, we analyzed the expression profile of human circRNAs in HCC tissues and identified circMTO1 (mitochondrial translation optimization 1 homologue; hsa_circRNA_0007874/hsa_circRNA_104135 ) as one circRNA significantly down‐regulated in HCC tissues. HCC patients with low circMTO1 expression had shortened survival. By using a biotin‐labeled circMTO1 probe to perform RNA in vivo precipitation in HCC cells, we identified miR‐9 as the circMTO1‐associated miRNA. Furthermore, silencing of circMTO1 in HCC could down‐regulate p21, the target of oncogenic miR‐9, resulting in the promotion of HCC cell proliferation and invasion. In addition, the tumor‐promoting effect of circMTO1 silencing was blocked by miR9 inhibitor. Intratumoral administration of cholesterol‐conjugated circMTO1 small interfering RNA promoted tumor growth in HCC‐bearing mice in vivo . Conclusion: circMTO1 suppresses HCC progression by acting as the sponge of oncogenic miR‐9 to promote p21 expression, suggesting that circMTO1 is a potential target in HCC treatment. The decrease of circMTO1 in HCC tissues may serve as a prognosis predictor for poor survival of patients. (H epatology 2017;66:1151‐1164).
Dimensions of environmental risk are unique theoretical constructs
Authors: Nicole Barbaro, Todd K Shackelford
Journal: Behavioral and Brain Sciences (2017)

Abstract Life history theory serves as the foundation for the CLimate, Aggression, and Self-control in Humans (CLASH) model of aggression. However, this model embodies several misunderstandings of life history constructs and principles. The CLASH model does not recognize that environmental harshness and environmental unpredictability are unique theoretical constructs, rendering predictions and implications from the model suspect.
Building a Broader Consensus for Health Reform
Authors: James C. Capretta
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Endometriosis research should aim to improve diagnosis and halt progression, meeting hears
Authors: Susan Mayor
Journal: BMJ (2017)

Improving the diagnosis of endometriosis and stopping its progression are key research priorities for the condition, agreed patients and health professionals responding to a survey published in the Lancet and presented at the World Congress on Endometriosis on 19 May.1

Endometriosis is common, affecting around one in 10 women during their reproductive years and having a similar prevalence to diabetes. But research into this chronic and painful condition is currently underfunded when compared with other common diseases.

The Endometriosis Priority Setting Partnership, set up by …
Anti-Leukemic Activity of the TYK2 Selective Inhibitor Ndi-031301 in T-Cell Acute Lymphoblastic Leukemia
Authors: Koshi Akahane, Zhaodong Li, Julia Etchin, Alla Berezovskaya, Evisa Gjini, Craig E Masse, Wenyan Miao, Jennifer Rocnik, Rosana Kapeller, Jeremy R Greenwood, Hong Tiv, Takaomi Sanda, David M Weinstock, A. Thomas Look
Journal: Blood (2016)
Clinical Significance of Lipid-Rich Plaque Detected by Optical Coherence Tomography
Authors: Lei Xing, Takumi Higuma, Zhao Wang, Aaron D. Aguirre, Kyoichi Mizuno, Masamichi Takano, Harold L. Dauerman, Seung-Jung Park, Yangsoo Jang, Chong-Jin Kim, Soo-Joong Kim, So-Yeon Choi, Tomonori Itoh, Shiro Uemura, Harry Lowe, Darren L. Walters, Peter Barlis, Stephen Lee, Amir Lerman, Catalin Toma, Jack Wei Chieh Tan, Erika Yamamoto, Krzysztof Bryniarski, Jiannan Dai, Thomas Zanchin, Shaosong Zhang, Bo Yu, Hang Lee, James Fujimoto, Valentin Fuster, Ik-Kyung Jang
Journal: Journal of the American College of Cardiology (2017)
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
Authors: Aaron James Scott, Bert H. O'Neil, Wen Wee Ma, Steven J. Cohen, Dara Aisner, Alex R. Menter, Mohamedtaki Abdulaziz Tejani, Jonathan K. Cho, Peter Rubin, Andrew L. Coveler, Olugbenga Olanrele Olowokure, Joaquina Celebre Baranda, Mike Cusnir, Philip Agop Philip, Jeremiah Boles, Robert T. Maguire, Francois Wilhelm, Manoj Maniar, Christina Gomes, Wells A. Messersmith
Journal: Journal of Clinical Oncology (2015)

4117 Background: Rigosertib (ON 01910.Na), a first-in-class Ras mimetic and small molecule inhibitor of multiple signaling pathways including polo-like kinase 1 (PLK1) and phosphoinositide 3-kinase (PI3K), has shown efficacy in preclinical pancreatic cancer models. In this study, rigosertib was assessed in combination with gemcitabine in patients with treatment-naïve metastatic pancreatic adenocarcinoma. Methods: Patients with metastatic adenocarcinoma of the pancreas were randomized in a 2:1 fashion to gemcitabine 1000 mg/m2 weekly for 3 weeks of a 4-week cycle plus rigosertib 1800mg/m2 via 2-hr continuous IV (CIV) infusions given twice weekly for 3 weeks of a 4-week cycle (RIG+GEM) versus gemcitabine 1000mg/m2 weekly for 3 weeks in a 4-week cycle (GEM). Results: A total of 160 patients were enrolled globally and randomly assigned to RIG+GEM (106 patients) or GEM (54). The most common grade 3 or higher adverse events were neutropenia (8% in the RIG+GEM group vs. 6% in the GEM group), hyponatremia (17% vs. 4%), and anemia (8% vs. 4%). The primary outcome of the study, median overall survival (OS), was 6.1 months for RIG+GEM versus 6.4 months for GEM (hazard ratio (HR), 1.24; 95% confidence interval [CI], 0.85-1.81). The median progression-free survival (PFS) was 3.4 months for both groups (HR = 0.96; 95% CI, 0.68-1.36). The partial response rate by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 was 19% versus 13% for RIG+GEM versus GEM, respectively. Of 64 tumor samples sent for molecular analysis, 47 were adequate for multiplex genetic testing and 41 were positive for mutations. The majority of cases had KRAS gene mutations (40/47, 85%). Other mutations detected included TP53 (13 cases) and PIK3CA(1 case). No correlation between mutational status and efficacy was detected. Conclusions: The combination of RIG+GEM failed to demonstrate an improvement in survival or response compared to GEM in metastatic pancreatic adenocarcinoma. Rigosertib had a similar safety profile to that observed in other trials of the IV formulation. Clinical trial information: NCT01360853.
Abstract 19850: Circulating Adhesion Molecules and Endothelial Function in Depressed Subjects With Coronary Risk Factors.
Authors: Carmine Pizzi, Lamberto Manzoli, Grazia Maria Costa, Raffaele Bugiardini
Journal: Circulation (2010)

Background:  Although several studies have shown an association between depression and increased morbidity and mortality for ischemic heart disease, the underlying mechanisms are unclear. The aim of this study was to investigate the relationship between molecular markers of atherosclerosis, endothelial dysfunction, and depression in patients free of coronary heart disease (CHD) with increased CHD risk.   Methods:  Depression status (Beck Depression Inventory, BDI), selected CHD risk factors, ICAM1 and indices of endothelial function (flow-mediated dilation, FMD) were evaluated in 415 subjects free of CHD, diabetes mellitus, and other life-threatening conditions, with at least two CHD risk factors among the following: older age, male gender, current smoking, hypertension, and dislipidaemia.   Results:  Overall, 51.7% of the participants were males, aged 57.6 ± 8.8 years on average (minimum 30, maximum 70). Almost half were hypertensive, 43.9% were dyslipidemic, 30.4% current smokers, and 23.1% showed a depressive symptomatology (BDI ≥ 10). Logistic regression showed that, as compared with non-depressed individuals and after adjustment for age, gender, and hypertension, depressive subjects were significantly more likely to be smokers, to have higher total cholesterol. In addition, depressed subjects were more likely to have altered ICAM-1 (adjusted odds ratio of 1 ng/mL increase= 1.2; 95% CI: 1.1-1.5) and their FMD was severely impaired (adjusted odds ratio of 1% increase = 0.72; 95% CI: 0.61-0.86).   Conclusion:  These data indicate an independent association between depression and impaired endothelial function and plasma levels of ICAM-1 as molecular marker for atherosclerosis and the depression symptoms. These mechanisms promote and/or accelerate the early disease and connect depression and CHD.
Endocannabinoid anandamide modulates the effects of paclitaxel to gastric cancer cells
Authors: Hideyo Miyato
Journal: Cancer Research (2007)

1925   Recently, cannabinoids, the active components of marijuana and their endogenous counterparts, have been shown to inhibit the growth of malignant tumors both in vitro and in vivo. On the other hand, the treatment of cancer cells with nanomolar concentrations of cannabinoids lead to accelerated cell proliferation. Orally applicable delta 9-tetrahydrocannabinol and its synthetic derivative have been approved by the United States Food and Drug Administration to be used as the antiemetic drugs during chemotherapy for cancer patients. However, it hasn’t been well known how cannabinoids modulate the effects of chemotherapeutic agents to malignant tumors.  In this study, we investigated how the endogenous cannabinoid anandamide (AEA) modulates the effect of paclitaxel to gastric cancer cell lines. In NUGC-3, 10μM AEA enhanced the effect of paclitaxel time-dependently and depending on the dose of paclitaxel. After 4 days treatment of 10μM paclitaxel, cell viability was reduced to 37.5% of control. Cell viability was further reduced to 7.1% after treatment of 10μM paclitaxel with 10μM AEA. The same effect was observed in HGC-27, AZ-521 and MKN-1. On the other hand, at nanomolar concentrations AEA did not change the cytotoxic effects of paclitaxel in those cell lines.  Double-stained with Annexin V-FITC and Propidium Iodide, 10μM AEA treatment of NUGC-3 and HGC-27 increased the population of annexinV (+) apoptotic cells, and enhanced paclitaxel-induced apoptosis. On the other hand, at nanomolar concentrations, AEA didn’t change the apoptosis induced by paclitaxel in NUGC-3. In cell cycle analysis 10μM AEA decreased G2/M arrest induced by paclitaxel and enhanced the increase of sub-G1 phase in NUGC-3 and HGC-27.  Our study indicates that AEA and paclitaxel could be a good combination in the treatment of gastric cancer and that medication of cannabinoids can be appropriately used in the treatment by paclitaxel.
Three-dimensional imaging system for colonoscopy
Authors: Tomoaki Matsumura, Hideaki Ishigami, Kenichiro Okimoto, Daisuke Maruoka, Tomoo Nakagawa, Mai Fujie, Makoto Arai
Journal: Endoscopy (2017)

Three-dimensional (3 D) imaging techniques have been developed in the medical field. In laparoscopic surgery, such techniques are widely used; they provide the surgeon with spatial information and increase the safety of surgical techniques [1] [2] [3]. In gastrointestinal endoscopy, Sakata et al. reported the efficacy of 3 D imaging for improved detection of colonic lesions using simulated 3 D colonoscopy [4]. However, to create a conventional 3 D image, two optical axes are required.
Knowledge Gaps in Cardiovascular Care of the Older Adult Population
Authors: Michael W. Rich, Deborah A. Chyun, Adam H. Skolnick, Karen P. Alexander, Daniel E. Forman, Dalane W. Kitzman, Mathew S. Maurer, James B. McClurken, Barbara M. Resnick, Win K. Shen, David L. Tirschwell
Journal: Circulation (2016)

The incidence and prevalence of most cardiovascular disorders increase with age, and cardiovascular disease is the leading cause of death and major disability in adults ≥75 years of age; however, despite the large impact of cardiovascular disease on quality of life, morbidity, and mortality in older adults, patients aged ≥75 years have been markedly underrepresented in most major cardiovascular trials, and virtually all trials have excluded older patients with complex comorbidities, significant physical or cognitive disabilities, frailty, or residence in a nursing home or assisted living facility. As a result, current guidelines are unable to provide evidence-based recommendations for diagnosis and treatment of older patients typical of those encountered in routine clinical practice. The objectives of this scientific statement are to summarize current guideline recommendations as they apply to older adults, identify critical gaps in knowledge that preclude informed evidence-based decision making, and recommend future research to close existing knowledge gaps. To achieve these objectives, we conducted a detailed review of current American College of Cardiology/American Heart Association and American Stroke Association guidelines to identify content and recommendations that explicitly targeted older patients. We found that there is a pervasive lack of evidence to guide clinical decision making in older patients with cardiovascular disease, as well as a paucity of data on the impact of diagnostic and therapeutic interventions on key outcomes that are particularly important to older patients, such as quality of life, physical function, and maintenance of independence. Accordingly, there is a critical need for a multitude of large population-based studies and clinical trials that include a broad spectrum of older patients representative of those seen in clinical practice and that incorporate relevant outcomes important to older patients in the study design. The results of these studies will provide the foundation for future evidence-based guidelines applicable to older patients, thereby enhancing patient-centered evidence-based care of older people with cardiovascular disease in the United States and around the world.